Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125549 | 0.92 | STAT3 (0.30) | STAT3 | |
| SCHEMBL18059323 | 0.86 | — | — | |
| SCHEMBL14107833 | 0.85 | STAT3 (0.32) | STAT3 | |
| SCHEMBL14107813 | 0.84 | STAT3 (0.37) | STAT3 | |
| SCHEMBL14107868 | 0.82 | STAT3 (0.31) | STAT3 | |
| SCHEMBL13089972 | 0.82 | STAT3 (0.31) | STAT3 | |
| SCHEMBL6655447 | 0.77 | PPM1D (0.33) | — | |
| SCHEMBL629011 | 0.76 | — | — | |
| SCHEMBL13090098 | 0.75 | — | — | |
| SCHEMBL2687928 | 0.75 | STAT3 (0.32) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2419403-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | Vidasym, Llc (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120698-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | STAT3 415/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | STAT3 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.